The pharmaceutical industry has spent the last two years debating whether direct-to-patient pharma business models are real. That debate is over.
Megan Shea
Advertisement
Megan Shea is a Director with Alvarez & Marsal's Life Sciences Group in Boston, Massachusetts. She is focused on advising Life Sciences companies including BioPharma, Pharmacy, MedTech, Diagnostics, and Wholesalers and Distributors, with experience advising private equity firms and life sciences corporations on M&A opportunities and corporate growth strategy. Her knowledge base spans the biopharma value chain including R&D, manufacturing, and commercialization, as well as the medical device and diagnostics industries.
Articles by Megan Shea
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
2
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma
3
FDA Pauses Release of New CRL’s Following Citizen’s Petition
4
Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement
5